Impact of pain on health-related quality of life in patients with inflammatory bowel disease

Schirbel, Anja; Reichert, A.; Roll, Stephanie; Baumgart, Daniel C.; Büning, Carsten; Wittig, B.; Wiedenmann, Bertram; Dignaß, Axel; Sturm, Andreas

doi:10.3748/wjg.v16.i25.3168

Cited by 135 publications

(112 citation statements)

References 47 publications

Supporting

Mentioning

107

Contrasting

Order By: Relevance

“…CrD is a lifelong disease characterized by various clinical symptoms including abdominal pain, weight loss, and bloody or non-bloody diarrhea [5]. The transmural inflammation characteristic for patients with CrD affects all layers of the bowel wall and adventitia [1].…”

Section: Autoimmunity In Crohn's Diseasementioning

confidence: 99%

Crohn’s disease specific pancreatic antibodies: clinical and pathophysiological challenges

Roggenbuck¹,

Reinhold

Schierack

et al. 2014

Clinical Chemistry and Laboratory Medicine

View full text Add to dashboard Cite

Crohn's disease (CrD) and ulcerative colitis (UC) are the main inflammatory bowel diseases (IBD). IBDspecific humoral markers of autoimmunity in the form of autoantibodies have been reported first in the late 1950s by demonstrating the occurrence of autoimmunity in UC, while humoral autoimmunity in CrD can be traced back to the 1970s. Ever since, the pathophysiological role of autoimmune responses in IBDs has remained poorly understood. Notwithstanding, autoreactive responses play a major role in inflammation leading to overt IBD. In CrD, approximately 40% of patients and < 20% of patients with UC demonstrate loss of tolerance to antigens of the exocrine pancreas. Glycoprotein 2 (GP2) has been identified as a major autoantigenic target of the so-called pancreatic antibodies. The previously unsolved contradiction of pancreatic autoreactivity and intestinal inflammation in IBD was elucidated by demonstrating the expression of GP2 at the site thereof. Intriguingly, GP2 has been reported to be a receptor on microfold cells of intestinal Peyer's patches, which are believed to represent the origin of CrD inflammation. The development of immunoassays for the detection of antibodies to GP2 has paved the way to investigate the association of such antibodies with the clinical phenotype in CrD. Given the recently discovered immunomodulating role of GP2 in innate and adaptive intestinal immunity, this association can shed further light on the pathophysiology of IBD. In this context, the association of anti-GP2 autoantibodies as novel CrD-specific markers with the clinical phenotype in CrD will be discussed in this review.

show abstract

Section: Autoimmunity In Crohn's Diseasementioning

confidence: 99%

Crohn’s disease specific pancreatic antibodies: clinical and pathophysiological challenges

Roggenbuck¹,

Reinhold

Schierack

et al. 2014

Clinical Chemistry and Laboratory Medicine

View full text Add to dashboard Cite

show abstract

“…10 Not only is pain highly prevalent, its impact on quality of life is far-reaching. Pain interferes with sleep, makes activities of daily living more difficult, limits social engagement, and is financially burdensome to individuals and their families (see, for example, references [11][12][13][14][15]. Furthermore, pain causes changes in neural function that outlast the precipitating disease or injury.…”

mentioning

confidence: 99%

Pain assessment using the NIH Toolbox

Cook

Dunn²,

Griffith³

et al. 2013

Neurology

109

View full text Add to dashboard Cite

Objective: Pain is an important component of health and function, and chronic pain can be a problem in its own right. The purpose of this report is to review the considerations surrounding pain measurement in the NIH Toolbox, as well as to describe the measurement tools that were adopted for inclusion in the NIH Toolbox assessment battery.Methods: Instruments to measure pain in the NIH Toolbox were selected on the basis of scholarly input from a diverse group of experts, as well as review of existing instruments, which include verbal rating scales, numerical rating scales, and graphical scales.Results: Brief self-report measures of pain intensity and pain interference were selected for inclusion in the core NIH Toolbox for use with adults. A 0 to 10 numerical rating scale was recommended for measuring pain intensity, and a 6-item Patient Reported Outcome Measurement Information System (PROMIS) short form for measuring pain interference. The 8-item PROMIS Pediatric Pain Interference measure was recommended as a supplemental measure. No specific measure was recommended for measuring pain intensity in children.Conclusions: Core and supplemental measures were recommended for the NIH Toolbox.Additional measures were reviewed for investigators who seek tools for measuring pain intensity in pediatric samples. Neurology Pain is an important component of health and function. The NIH Toolbox somatosensation team took responsibility for considering the best methods for evaluating pain in the general population. In the International Classification of Functioning, Disability and Health, sensory functions and pain are grouped together as body functions; however, sensation of pain is distinguished from sensory functions such as proprioception or touch, as well as functions related to temperature and other stimuli. 1 The definition of somatosensory function includes the "detection, discrimination, and recognition" of pain (Dunn et al., this issue). However, pain is more than a biological process and can be integral to function, role participation, and overall quality of life. As such, its assessment often becomes a primary end point in clinical trials and treatment effectiveness studies. This led the Toolbox team to consider pain and its assessment in parallel with somatosensory function and to dedicate separate manuscripts to discussions of pain and somatosensation.The science of pain measurement has benefited from recent advances in measurement approaches and applications.2-4 The field of outcomes research has well-developed, self-reported pain measures that have been validated in a range of acute and chronic medical conditions. For this reason, the team chose not to develop new pain measures but to adopt existing instruments that would add to the battery of tests included in the NIH Toolbox. In this article, we describe the importance of pain to the assessment of health and discuss its multidimensional nature. We

show abstract

“…: diarrhea and rectal bleeding, abdominal pain, cramps, and joint pain), as the disease is characterized by chronic recurrent ulceration of the bowels. However, it is known that IBD patients suffering from pain have decreased health related quality of life [42]. An optimization of the follow-up pain management would include more than a regular screening tool assessing abdominal pain; indeed, that would mean a multifactorial pain cause assessment (including joint pains [43,44]) with the assessment of psychosocial consequences, that is, stress and quality of life.…”

Section: Discussionmentioning

confidence: 99%

“…Pain has mostly multifactorial etiologies; therefore, it is advised to treat IBD patients with individualized plans [45] that might include supportive therapy such as cognitive behavioral, stress management, coping, acupuncture and nerve blocks, and antidepressants [45]. Schirbel et.al stress the underestimation of pain intensity often done by healthcare providers during follow-up care [42]. Clinical anxiety (HADS >10) (9.3%) and depression scores (HADS >10) in our patient sample (6.7%) were very low compared with those of a Spanish study including 875 IBD patients, reporting that 10.5% had clinical anxiety and 20.1% had depression [46].…”

Section: Discussionmentioning

confidence: 99%

Assessment of Inflammatory Bowel Disease Patient's Needs and Problems from a Nursing Perspective

et al. 2015

View full text Add to dashboard Cite

Background: In this study, we aimed at assessing Inflammatory Bowel Disease patients' needs and current nursing practice to investigate to what extent consensus statements (European Crohn's and Colitis Organization) on the nursing roles in caring for patients with IBD concur with local practice. Methods: We used a mixed-method convergent design to combine quantitative data prospectively collected in the Swiss IBD cohort study and qualitative data from structured interviews with IBD healthcare experts. Symptoms, quality of life, and anxiety and depression scores were retrieved from physician charts and patient self-reported questionnaires. Descriptive analyses were performed based on quantitative and qualitative data. Results: 230 patients of a single center were included, 60% of patients were males, and median age was 40 (range 18-85). The prevalence of abdominal pain was 42%. Self-reported data were obtained from 75 out of 230 patients. General health was perceived significantly lower compared with the general population (p < 0.001). Prevalence of tiredness was 73%; sleep problems, 78%; issues related to work, 20%; sexual constraints, 35%; diarrhea, 67%; being afraid of not finding a bathroom, 42%; depression, 11%; and anxiety symptoms, 23%. According to experts' interviews, the consensus statements are found mostly relevant with many recommendations that are not yet realized in clinical practice. Conclusion: Identified prevalence may help clinicians in detecting patients at risk and improve patient management.

show abstract

Impact of pain on health-related quality of life in patients with inflammatory bowel disease

Abstract: Most IBD patients suffer from pain and have decreased HRQOL. Our study reinforces the need for effective individualized pain therapy in IBD patients.

Cited by 135 publications

References 47 publications

Crohn’s disease specific pancreatic antibodies: clinical and pathophysiological challenges

Crohn’s disease specific pancreatic antibodies: clinical and pathophysiological challenges

Pain assessment using the NIH Toolbox

Assessment of Inflammatory Bowel Disease Patient's Needs and Problems from a Nursing Perspective

Contact Info

Product

Resources

About